PiXL KXL II

Introducing KXL II™ and Photorefractive
Intrastromal Cross-linking (PiXL™)
the next revolution in refractive correction
The KXL® and KXL™ II Systems for performing Lasik Xtra® and Accelerated Cross-linking are not for sale in the United
States. VibeX RapidTM, VibeX XtraTM, and ParaCelTM are not for sale in the United States. MA-00266 Rev A
KXL II PiXL
The Future of Cross-linking
expanding the possibilities for your practice
Avedro’s KXL II System
allows patterned,
precise, topography-guided accelerated
cross-linking with:
• Programmable and customizable illumination
patterns
• Seamless integration with leading industry
topographers
• Real-time eye tracking
• Significantly higher power output
Procedures performed with the KXL II
System include PiXL, Lasik Xtra® and
Accelerated Cross-linking. These
procedures have the potential to:
• Enhance cataract surgery without
surgical intervention
• Provide non-surgical refractive
correction
• Restore biomechanical integrity
• Treat pathology with methods
unavailable in other devices
KXL II is CE Marked and not
available for sale in the US.
Visit avedro.com/kxl to learn more.
Myopic Treatment
Pre-Treatment
Post-Treatment
Difference
Images courtesy of A. John Kanellopoulos, MD
PiXL is only available with
Avedro’s KXL II System.
What the Experts are Saying:
“
“As one of the first KXL II clinical sites, we experienced the amazing
capabilities of customized accelerated cross-linking to achieve specific,
reproducible and interim-stable refractive changes on the cornea. It
seems to me that every surgeon who has performed cross-linking has
experienced refractive corneal changes. We now have a way to design and
customize these refractive changes. If these initial clinical results continue
to be repeated, as I believe they will, the potential seems unlimited.”
— A. John Kanellopoulos, MD
”
“Through my involvement in the early stages of scientific development,
I have experienced firsthand the potential that the KXL II has to truly
change ophthalmology and to open up refractive correction to
millions of patients.
— John Marshall, MBE, PhD
Avedro
is a privately held medical device and pharmaceutical company advancing the science
and technology of corneal cross-linking and refractive correction. Avedro’s products include
capital equipment and related single dose pharmaceuticals. Those products are currently used to
enhance Lasik outcomes in a procedure known as Lasik Xtra. Over 75,000 surgeries have been
successfully performed outside the US using Avedro’s KXL System. The KXL System’s accelerated
cross-linking, in combination with its pharmaceuticals, is also used to treat several important and
debilitating ophthalmic pathologies.
Avedro’s KXL and pharmaceutical products are currently being used in three Phase III US clinical
trials involving over 100 clinical sites.
Avedro distributes its products in 62 countries through 33 ophthalmic distributors with 115
representatives. Avedro products are not for sale in the US.
781.768.3400 | [email protected] | www.avedro.com
The KXL® and KXL™ II Systems for performing Lasik Xtra® and Accelerated Cross-linking are not for
sale in the United States. VibeX RapidTM, VibeX XtraTM, and ParaCelTM are not for sale in the United
States. MA-00266 Rev A

Download Report